Experimental cell therapy trial launches for aggressive recurrent brain tumors
NCT ID NCT07384390
Summary
This early-phase study is testing a new cell therapy called TH-CART-027 for adults with recurrent or progressive grade 4 glioma, a very aggressive type of brain cancer. The main goals are to find a safe dose and see if the treatment can shrink tumors. Researchers will enroll 21 participants who have already tried standard treatments and whose tumor cells show a specific marker.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.